AVR logo

ANTERIS TECHNOLOGIES GLOBAL

AVRNASDAQ
πŸ† #2227 by market capUS Equity
$8.65β–Ό $0.49 (βˆ’5.67%)
Live
1hβ–Ό 0.2%
24hβ–Ό 5.7%
7dβ–² 7.6%
14dβ–² 9.4%
30dβ–Ό 7.5%
1yβ–² 135.7%
🏦Market Cap
$842M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-0.5%
Declining
πŸ“ŠGross Margin
74.3%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
471.2x
Expensive
Otter Score
46
Weak

Trading Snapshot

Day Range
$8.58 – $8.77
52-Week Range
$3.18 – $11.06
Volume
$3.12B
Avg Volume
$2.65B
Shares Outstanding
97.3M
Next Earnings
Sep 9, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$1M
P/E Ratio
β€”
P/S Ratio
471.2x
EPS (TTM)
$-2.21
Dividend Yield
β€”

Why Investors Own AVR

  • βœ“High-growth profile β€” revenue up +11.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 77% gross margin and 12% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2Mβ–² +9.3% YoY
Gross Margin (TTM)
77.2%β–² +2.9% YoY
Operating Income (TTM)
$160,692β–² +9.3% YoY
Free Cash Flow (TTM)
$227,647β–² +9.3% YoY

About ANTERIS TECHNOLOGIES GLOBAL

Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
46/100

Analyst Ratings

β“˜
Consensus
Buy
8 analysts
Strong Buy1
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates